Insider activity at Ovid Therapeutics Inc. has been all selling for a year now: about $29,000 from two sellers, and zero buyers with their own money.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Big money check: 131 institutions held OVID as of Q2 2026, and more funds bought than sold. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Rona Jeffrey A | Officer | Sell | 8,541 | $1.45 | $12K | SEC |
| Mar 2, 2026 | ALEXANDER MARGARET A. | CEO | Sell | 11,656 | $1.45 | $17K | SEC |
| Feb 28, 2025 | ALEXANDER MARGARET A. | COO | Sell | 5,279 | $0.56 | $3K | SEC |
| Feb 28, 2025 | Rona Jeffrey A | Officer | Sell | 3,902 | $0.56 | $2K | SEC |
| Jan 29, 2025 | ALEXANDER MARGARET A. | COO | Buy | 6,810 | $0.73 | $5K | SEC |
| Mar 20, 2024 | LEVIN JEREMY M | CEO | Buy | 18,248 | $2.76 | $50K | SEC |
In the last 12 months Ovid Therapeutics Inc. insiders made open-market purchases worth about $0 and sales worth about $29,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in OVID was filed on 2026-03-02.
131 investment managers reported holding OVID in SEC Form 13F filings for Q2 2026.
No congressional trades in OVID were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).